The early-stage trial will study safety, pharmacokinetics, and pharmacodynamics of VE-1902 in 100-120 participants. The blood thinner is the first PRrecision Oral AntiCoagulant (PROAC) of the US-based pharma
The post Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant appeared first on Pharmaceutical Business review.
Original Article: Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant